{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:32:37Z","timestamp":1785407557798,"version":"3.56.0"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007683","name":"Nihon University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007683","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/05jk51a88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Hyperuricemia is an adverse effect frequently observed during favipiravir treatment. The time course, from uric acid elevation to recovery, and quantitative relationship between drug exposure and changes in serum uric acid levels remain insufficiently characterized. We investigated the pharmacodynamic mechanism of uric acid elevation and described its time course by population pharmacokinetic and pharmacodynamic modelling. Methods: Patients who received favipiravir for coronavirus disease 2019 or severe fever with thrombocytopenia syndrome were retrospectively evaluated. The pharmacokinetics of favipiravir were described by a one-compartment model with first-order absorption and elimination. Metabolite concentrations were predicted based on previously reported values. Changes in serum uric acid levels were described by a turnover model with zero-order production and first-order elimination. The drug effect was implemented as inhibition of the uric acid elimination process. Simulations based on the final model were performed for 10 consecutive days after the clinical regimen, with a 21-day follow-up. Results: The final model supported the inhibition of uric acid elimination by favipiravir and its metabolite. Regarding simulations, serum uric acid levels reached a median peak of 6.93 mg\/dL at 6.7 days after treatment initiation and returned to pre-treatment levels within 4.0 days after treatment discontinuation. Conclusions: This combined population pharmacokinetic and pharmacodynamic turnover model quantified favipiravir-associated increases in serum uric acid levels and showed a transient profile with rapid recovery after drug discontinuation. These findings underscore the need for monitoring serum uric acid levels during favipiravir treatment, particularly in patients at a higher risk of gout.<\/jats:p>","DOI":"10.3390\/ph19071008","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:27:37Z","timestamp":1782746857000},"page":"1008","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Analysis and Modelling of Serum Uric Acid Dynamics in Patients Treated with Favipiravir"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1370-4202","authenticated-orcid":false,"given":"Tomona","family":"Yamada","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-101X","authenticated-orcid":false,"given":"Hitoshi","family":"Kawasuji","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Ogami","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9455-5638","authenticated-orcid":false,"given":"Daichi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satofumi","family":"Iida","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy, 601 Matano-cho, Totsuka-ku, Kanagawa 245-0066, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6111-8537","authenticated-orcid":false,"given":"Takahiko","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-8724","authenticated-orcid":false,"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-2947","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a Broad Spectrum Inhibitor of Viral RNA Polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A New and Emerging Antiviral Option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med. J. Armed Forces India"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"110042","DOI":"10.1016\/j.virol.2024.110042","article-title":"New Perspective of Small-Molecule Antiviral Drugs Development for RNA Viruses","volume":"594","author":"Li","year":"2024","journal-title":"Virology"},{"key":"ref_4","unstructured":"Fujifilm Toyama Chemical Co., Ltd. (2024). Avigan\u00ae (Favipiravir) Package Insert, Fujifilm Toyama Chemical Co., Ltd."},{"key":"ref_5","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) (2014). Report on the Deliberation Results: Avigan, Pharmaceuticals and Medical Devices Agency (PMDA)."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/cts.12827","article-title":"Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19","volume":"13","author":"Irie","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1111\/bcp.15227","article-title":"Pharmacokinetic Characterization of Favipiravir in Patients with COVID-19","volume":"88","author":"Toplu","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e13980","DOI":"10.1111\/apha.13980","article-title":"Uric Acid Transport, Transporters, and Their Pharmacological Targeting","volume":"238","author":"Adomako","year":"2023","journal-title":"Acta Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00467-013-2549-x","article-title":"Uric Acid and the Kidney","volume":"29","author":"Cramer","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5049\/EBP.2021.19.1.1","article-title":"Urate Transporters in the Kidney: What Clinicians Need to Know","volume":"19","author":"Chung","year":"2021","journal-title":"Electrolytes Blood Press."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.23876\/j.krcp.24.321","article-title":"Role of Urate Transporters in the Kidneys and Intestine in Uric Acid Homeostasis","volume":"45","author":"Kim","year":"2025","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1620\/tjem.251.87","article-title":"Uric Acid Elevation by Favipiravir, an Antiviral Drug","volume":"251","author":"Mishima","year":"2020","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115640","DOI":"10.1016\/j.diagmicrobio.2022.115640","article-title":"Evaluation of Risk Factors for Uric Acid Elevation in COVID-19 Patients Treated with Favipiravir","volume":"102","author":"Hanai","year":"2022","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijid.2021.12.324","article-title":"Baseline Uric Acid Levels and Steady-State Favipiravir Concentrations Are Associated with Occurrence of Hyperuricemia Among COVID-19 Patients","volume":"115","author":"Koseki","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar1909","article-title":"Recent Developments in Our Understanding of the Renal Basis of Hyperuricemia and the Development of Novel Antihyperuricemic Therapeutics","volume":"8","author":"Terkeltaub","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11926-007-0040-z","article-title":"Uric Acid Nephrolithiasis","volume":"9","author":"Liebman","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/a-2061-7074","article-title":"Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-Vitro In-Vivo Correlation","volume":"73","author":"Bendas","year":"2023","journal-title":"Drug Res."},{"key":"ref_19","first-page":"1","article-title":"Pharmacokinetics and Bioequivalence Study of Two Formulations of Favipiravir 200 Mg Film-Coated Tablet in Healthy Indonesian Volunteers","volume":"7","author":"Priyanto","year":"2023","journal-title":"Bioequivalence Bioavailab. Int. J."},{"key":"ref_20","first-page":"1000436","article-title":"Bioequivalence Study of Favipiravir 200 Mg Tablets in Healthy Thai Volunteers under Fasting Conditions","volume":"13","author":"Yoosakul","year":"2021","journal-title":"J. Bioequivalence Bioavailab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5414\/CP203936","article-title":"Bioequivalence Study of Two Favipiravir Tablet Formulations in Healthy Male Subjects","volume":"59","author":"Saraner","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/psp4.12685","article-title":"Population Pharmacokinetics of Favipiravir in Patients with COVID-19","volume":"10","author":"Irie","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103125","DOI":"10.1016\/j.ebiom.2020.103125","article-title":"Phase 2a, Open-Label, Dose-Escalating, Multi-Center Pharmacokinetic Study of Favipiravir (T-705) in Combination with Oseltamivir in Patients with Severe Influenza","volume":"62","author":"Wang","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3851\/IMP3210","article-title":"Pharmacokinetics of Favipiravir During Continuous Venovenous Haemofiltration in a Critically Ill Patient with Influenza","volume":"23","author":"Murk","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Qu, G., Huang, G., Zhang, M., Yu, H., Song, X., Zhu, H., Chen, L., Wang, Y., and Pei, B. (2020). Features of C-Reactive Protein in COVID-19 Patients with Different Ages, Clinical Types and Outcomes: A Cohort Study. medRxiv, 2020.10.26.20220160.","DOI":"10.1101\/2020.10.26.20220160"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3126\/jngmc.v20i1.48347","article-title":"C-Reactive Protein as a Prognostic Marker in Hospitalized Patients with COVID-19","volume":"20","author":"Shrestha","year":"2022","journal-title":"J. Nepalgunj Med. Coll."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of Four Basic Models of Indirect Pharmacodynamic Responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1208\/s12248-014-9709-1","article-title":"Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers","volume":"17","author":"An","year":"2015","journal-title":"AAPS J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1248\/bpb.b15-01031","article-title":"Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid","volume":"39","author":"Hirai","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"ref_30","first-page":"sp-1\u2013sp-40","article-title":"Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd Edition","volume":"44","author":"Hisatome","year":"2020","journal-title":"Gout Uric Nucleic Acids"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2169\/internalmedicine.5377-20","article-title":"Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019","volume":"59","author":"Hase","year":"2020","journal-title":"Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H.T., Guedj, J., Anglaret, X., Laou\u00e9nan, C., Madelain, V., Taburet, A.M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower than Targeted. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to Fit a PK Model with Some Data below the Quantification Limit","volume":"28","author":"Beal","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/B:JOPA.0000012999.36063.4e","article-title":"Simultaneous vs. Sequential Analysis for Population PK\/PD Data II: Robustness of Methods","volume":"30","author":"Zhang","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","article-title":"Simultaneous vs. Sequential Analysis for Population PK\/PD Data I: Best-Case Performance","volume":"30","author":"Zhang","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"\u0141agocka, R., Dziedziejko, V., K\u0142os, P., and Pawlik, A. (2021). Favipiravir in Therapy of Viral Infections. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020273"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A Pharmacokinetic Standard for Babies and Adults","volume":"102","author":"Holford","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The Search for Synergy: A Critical Review from a Response Surface Perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A Procedure for Generating Bootstrap Samples for the Validation of Nonlinear Mixed-Effects Population Models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput. Methods Programs Biomed."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:13:44Z","timestamp":1783656824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ph19071008"],"URL":"https:\/\/doi.org\/10.3390\/ph19071008","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}